Cook Isla¹, Murphy Aaron², Morgan Sienna³, Reed Nathan⁴, Bell Madison⁵, Cooper Ezra⁶, Bailey Hannah⁷, Rivera John⁸
ABSTRACT:
Cardiomyopathies represent a heterogeneous group of myocardial disorders with diverse etiologies and clinical manifestations. This review explores the evolving landscape of biomarkers for cardiomyopathies, spanning from established genetic markers to emerging serum protein signatures. We discuss genetic mutations in sarcomeric, cytoskeletal, and desmosomal proteins; novel circulating biomarkers reflecting myocardial stress, fibrosis, and metabolic derangements; multi-omics approaches integrating genomic, proteomic, and metabolomic data; and clinical applications for early diagnosis, risk stratification, and personalized treatment. Special emphasis is placed on biomarker-guided management strategies and future directions in precision cardiology.